Objective
To explore the potential efficacy of multi‐modular motion‐assisted memory desensitization and reprocessing (3MDR) in British military veterans with treatment‐resistant service‐related PTSD.
Methods
Exploratory single‐blind, randomized, parallel arm, cross‐over controlled trial with nested process evaluation to assess fidelity, adherence and factors that influence outcome.
Results
A total of 42 participants (all male) were randomized with 83% retention at 12 weeks and 86% at 26 weeks. The difference in mean Clinician‐Administered PTSD Scale for DSM‐5 scores between the immediate and delayed 3MDR arms was −9.38 (95% CI −17.33 to −1.44, P = 0.021) at 12 weeks and −3.59 (−14.39 to 7.20, P = 0.513) at 26 weeks when both groups had received 3MDR. The likely effect size of 3MDR was found to be 0.65. Improvements were maintained at 26‐week follow‐up. 3MDR was found to be acceptable to most, but not all, participants. Several factors that may impact efficacy and acceptability of 3MDR were identified.
Conclusion
3MDR is a promising new intervention for treatment‐resistant PTSD with emerging evidence of effect.